Bristol Cements Lead In Immunotherapy

FDA approval for Opdivo and Yervoy in combination and Opdivo as monotherapy for the treatment of all metastatic melanoma patients, regardless of BRAF mutation status, puts Bristol on equal footing with Merck in the indication, and positions it to take on the BRAF inhibitors.